PEDS Advance Access originally published online on July 13, 2004
Protein Engineering Design and Selection 2004 17(5):417-424; doi:10.1093/protein/gzh051
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Different elements of mini-helix 1 are required for human growth hormone or prolactin action via the prolactin receptor
1The Ohio State Biochemistry Program, 2Department of Veterinary Biosciences and 3Department of Biochemistry, The Ohio State University, 1925 Coffey Road, Columbus, OH 43210, USA
4 To whom correspondence should be addressed. E-mail: brooks.8{at}osu.edu
Human growth hormone (hGH) and prolactin (hPRL) have a low sequence homology, but both bind and activate hPRL receptors. hGH also binds hGH receptors. hGH has 22 and 20 kDa forms; residues 3246 have been deleted by alternative RNA splicing to create the smaller form. hGH requires F44 for activity through the hPRL receptor, but not for activity through the hGH receptor. The deletion of F44 from hGH has the same effect as removal of residues 3246 (
200-fold loss in activity), indicating the importance of F44 in hGH when activating the hPRL receptor. In contrast, when the homologous F50 is deleted from hPRL little or no activity is lost, indicating that this highly conserved phenylalanine is not required for the action of hPRL. Deletion of residues 4152 (a non-conserved sequence homologous to residues 3246 of hGH) reduced the activity of hPRL by >14 000-fold. This region is essential for the biological activity of hPRL. As these two proteins have evolved from a common ancestor, they have retained the requirement for this region but need different structural elements to activate hPRL receptors. Such diversity represents an opportunity to fine-tune hormone activity.
Received February 12, 2004; revised April 29, 2004; accepted May 21, 2004.
Edited by Andreas Kungl
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. A. Svensson, K. Bondensgaard, L. Norskov-Lauritsen, L. Christensen, P. Becker, M. D. Andersen, M. J. Maltesen, K. D. Rand, and J. Breinholt Crystal Structure of a Prolactin Receptor Antagonist Bound to the Extracellular Domain of the Prolactin Receptor J. Biol. Chem., July 4, 2008; 283(27): 19085 - 19094. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Polgar, B. Fogelgren, J. M. Shipley, and K. Csiszar Lysyl Oxidase Interacts with Hormone Placental Lactogen and Synergistically Promotes Breast Epithelial Cell Proliferation and Migration J. Biol. Chem., February 2, 2007; 282(5): 3262 - 3272. [Abstract] [Full Text] [PDF] |
||||
